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ABSTRACT
The standard of care for patients with newly diagnosed Glioblastoma multiforme 
(GBM) has remained unchanged since 2005, with patients undergoing maximal 
surgical resection, followed by radiotherapy plus concomitant and maintenance 
Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become 
FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-
11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment 
which utilizes medium frequency alternating electric fields to target actively dividing 
cancerous cells. TTFields selectively targets cells within mitosis through interacting 
with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy 
presents itself as a candidate for the combinational therapy route due to the lack 
of overlapping toxicities associated with electric fields. Here we review current 
literature pertaining to TTFields in combination with alkylating agents, radiation, 
anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. 
This review highlights the observed synergistic and additive effects of combining 
TTFields with various other therapies, as well highlighting the strategies relating to 
combinations with electric fields.
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INTRODUCTION
The use of electric fields for the treatment of 
neurological disorders pre-dates its use in the treatment 
of glioma [1]. Electric fields administered to the brain 
demonstrate profound effects specific to the parameters 
used – being frequency (Hertz – Hz), intensity (Volts – V) 
and pulse-width (Seconds – s). This review will focus on 
the Optune™ technology relevant to the treatment of brain 
tumours. 
OPTUNE™ (FORMERLY KNOWN AS 
NOVOTTF-100A)
The Optune system is a US Food and Drug 
Administration (FDA) approved novel anti-mitotic 
device that delivers continuous alternating electric fields 
to the patient for the treatment of primary and recurrent 
Glioblastoma multiforme (GBM). Optune is indicated 
for patients which are of at least 22 years of age, with 
histologically confirmed supratentorial GBM (WHO 
grade IV astrocytoma [2]). Optune in combination with 
Temozolomide (TMZ) has been approved for use in adult 
patients with newly diagnosed GBM following maximal 
safe resection, as well as completion of radiation therapy 
with concomitant TMZ [3]. 
The Optune system is composed of four transducer 
arrays, a field-generator, and a power source (Figure 1). 
The field-generator delivers electric fields through the 
insulated transducer arrays which are applied to the 
shaved scalp of the patient. The field-generator delivers 
pre-set electric fields (200 kHz for glioma as determined 
by Kirson et al. [4] and with a minimum field intensity of 
1.0 V/cm [5] – termed tumour treating fields (TTFields)) 
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throughout the tumour in a non-invasive manner [6]. 
Much progress has also been made with optimisation of 
transducer layout in order to deliver a more efficacious 
treatment to improve patient outcome. The optimal array 
placement on the patient’s scalp is calculated using 
NovoTAL™ (Novocure Ltd., Haifa, Israel) simulation 
software, which will look to optimise field intensity within 
the tumour with variables such as tumour loci and patient’s 
head measurements [7]. 
A single transducer array is composed of 9 insulated 
biocompatible ceramic disks. A conductive hydrogel is 
applied to the patient’s shaven scalp to prevent direct 
contact of the ceramic disks and scalp. Thorough and 
frequent shaving of the patient’s scalp is required for 
optimal contact between the transducer arrays and skin. 
Application of the transducer arrays to the scalp of the 
patients is not a sterile process, however the prescribed 
transduced arrays are supplied in individual sterile 
packages in order to reduce risk of infection. For GBM 
patient’s, Optune TTFields therapy is delivered through 
two pairs of orthogonally positioned transducer arrays 
on the patient’s scalp. These particular components 
are secured in place, with emphasis on continuous skin 
contact, by being attached to a hypoallergenic medical 
adhesive bandage. A single cable connects each transducer 
array to the portable field generator component of the 
Optune system [6]. A critique of the Optune system was 
the cumbersome nature of the field-generator, however 
this has been addressed with the production of a second 
generation design – yielding a reduction in total weight of 
over 50% (https://www.optune.com/hcp/therapy/system). 
A number of contraindications are associated 
with the Optune system which could discourage uptake. 
Firstly, the effects of TTFields have only been studied 
with adults, therefore Optune TTFields therapy may only 
be administered to patients of 22 years or older. Patients 
are excluded from treatment if they have a skull defect 
which would restrict attachment of the transducer arrays, 
and also if they have known sensitivity to conductive 
hydrogels (https://www.optune.com/Content/pdfs/Optune_
IFU_8.5x11.pdf). Medically implanted devices (such 
as DBS devices) were removed from the list of official 
contraindications due to a retrospective analysis of 1,402 
patients which revealed no device related safety concerns 
for the 49 patients with implanted medical devices [8]. 
Lastly, considerations have to be made regarding patients 
without access to assistance with the Optune system (either 
a friend/relative or carer) or do not have sufficient mental 
competence for personal maintenance of and compliance 
with the system, as patients are expected to comply to the 
system on average at least 18 hours per day [9].
TTFIELDS MECHANISMS OF ACTION
Understanding the approach of TTFields requires 
familiarity with three concepts. Firstly, electric fields 
may be uniform – an electric field which is constant at 
every point in space, or non-uniform – an electric field 
which varies in magnitude and/or direction (convergent 
or divergent) at a given point in space [10]. Secondly, an 
electric field may be a constant field – where the source 
charge remains constant such that a test charge will 
Figure 1: The Optune System. (Left) The Optune System as worn by a patient. (Right) The Optune System consisting of a field 
generator connected to a transducer array, with the included backpack to facilitate portability of the field generator.
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converge, in a single direction, within the constant field 
towards the opposite polarity source. An electric field 
may also be a time-varying field – where the charges of 
the sources do not remain constant and therefore alternate 
space [10]. Lastly, the test charge may either be an electric 
monopole or an electric dipole. An electric monopole will 
simply alternate direction of travel along an alternating 
uniform field, however, an electric dipole will spin within 
the alternating uniform field while orientating with its 
current direction. Both electric monopoles and dipoles will 
travel towards the point of greatest electric field intensity 
within a converging non-uniform field – a process known 
as dielectrophoresis [10].
The concept of treating cancer through targeting 
dividing tumour cells with TTFields was originally raised 
by Prof. Yoram Palti, Israel Institute of Technology [4]. 
The initial theory was that mitotic activity of tumour cells 
could be disrupted with the application of alternating 
electrical fields and become a potential therapeutic 
avenue [4]. Palti and colleagues tested this hypothesis 
on eleven different cell lines, with multiple cancer types, 
and subsequently demonstrated that the formation of 
mitotic spindles could be disrupted by TTFields. More 
specifically, Palti and colleagues showed that TTFields 
interfered with polymerization of tubulin subunits, a 
necessary process within metaphase required for cell 
division [4]. Other notable conclusions of the study were 
the significance of optimising the TTFields, to a specific 
cancer type, to exhibit maximal effectiveness without the 
consequences of excessive tissue heating or stimulation. 
These parameters being an intermediate frequency (200 
kHz) with a low intensity (1–3 V/cm) for glioma cell lines 
[4]. The considerations of these parameters is necessary 
to avoid unwanted membrane depolarization of excitable 
cells and tissue heating [11]. However, these undesirable 
stimulations greatly decline when the frequency of an 
alternating electric field increases above 1kHz because of 
the excitable membranes’ hyperpolarization/depolarization 
cycles becoming integrated due to a membrane’s 
excitability response time simply being too slow to handle 
such high frequencies [4, 11]. Conversely, exceptionally 
high frequencies, within the MHz range, cause greater 
integration of the hyperpolarization/depolarization cycles 
resulting in dielectric losses – electrical heating as a result 
of rapidly oscillating molecules [4, 11]. 
Anti-mitotic effects of TTFields
As highlighted previously, living cells respond to 
electric fields due to intracellular polar molecules being 
susceptible to electrical manipulation. Of particular 
interest is the mechanism and interactions of TTFields 
with these polar molecules during mitosis, as this is 
where TTFields may express their anti-tumour effects 
[4, 12–14].
Firstly, the detailed intricacies of mitosis are beyond 
the scope of this review. However, certain events during 
this process are paramount to the understanding of 
how TTFields function and have therapeutic potential. 
Before the actualisation of the metaphase-plate, paired 
centromeres are captured by the ends of microtubules, 
before becoming orientated towards their respective 
poles by their opposing metaphase spindles, during 
anaphase to become separated via cytokinesis [12, 15]. 
Sister chromatid separation through cytokinesis is a 
consequence of Cyclin B and Securin ubiquitin-mediated 
degradation by Cdc20 and Anaphase Promoting Complex 
C (APC/C) [12, 15, 16]. This APC/CCdc20 destruction 
complex is dependent on proper microtubule localisation 
and function within the anaphase and metaphase spindles 
[12, 15, 16]. The key point of this process is that errors 
that disrupt this intricate process, particularly following 
commitment to anaphase, are likely to be irrevocable [17]. 
This dependency of cancer cells on mitotic competence 
is the basis for a number of therapies targetting mitosis 
[18], and is also the basis of TTFields as previously stated, 
errors committed within anaphase results in a multitude of 
cell fates and phenotypes including mitotic catastrophe, 
aberrant mitotic exit, aneuploidy, multi-nucleation, mitotic 
slippage and apoptosis [12, 14, 19]. 
One of the processes which TTFields target is 
tubulin polymerization [4, 10, 12, 14]. Microtubules 
consist of polymerized tubulin dimers, arranged around 
a hollow core in parallel [20]. The dynamic instability 
of microtubules is particularly crucial for cytoskeleton 
remodelling which occurs during mitosis, simply 
put, tubulin dimers undergo expeditious cycles of 
polymerisation and depolymerisation. Both α-tubulin 
and β-tubulin are bound to guanosine triphosphate (GTP) 
which in turn regulates the polymerization process, and it 
is the hydrolysis of GTP, bound to β-tubulin, to guanosine 
diphosphate which favours depolymerisation [20, 21]. In 
summary, microtubule formation is determined by the rate 
of tubulin polymerization relative to the rate of tubulin 
depolymerisation/GTP hydrolysis. Therefore, TTFields 
would promote depolymerisation, given that tubulins are 
among the most polar molecules within cells [10, 22], by 
causing misalignment of tubulin subunits as they become 
forced to align with the electric field rather than their 
respected microtubule filament axis [10, 22]. This in turn 
promotes hydrolysis of GTP to GDP at the positive end 
of the microtubule, dissociation of tubulin subunits and 
overall microtubule disruption [20].
Given that TTFields affect mitosis through their 
effects on proteins that possess a high dipole moment 
and significance within the mitotic process, it would 
be reasonable to assume that TTFields would interact 
with a large number of proteins. Recently, Gera et al. 
showed the effects of TTFields on other key mitotic 
proteins and that TTFields express a more diverse 
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interaction than once thought [12]. Gera et al. focussed 
on the Septin heterotrimer (Referred to as Septin from 
now on), composed of Septin 2, 6 and 7, due to its large 
dipole moment of 2711D as well as its interaction with 
the cytokinetic cleavage furrow (CCF) formation [12]. 
Of note is the dipole moment of Septin which is larger 
than the dipole moment of tubulin dimers (1660D). 
Other components of the CCF were excluded from the 
analysis due to incomplete crystal structure information 
prohibiting dipole moment calculations, including Anillin 
and PLK1 [12]. The significance of Septin resides within 
the anaphase spindle midline and CCF, where through 
cooperation with Anillin, stabilisation of microtubule 
structures and the boundaries of the CCF contractility 
are distinguished [12, 23, 24]. Anillin functions as an 
adaptor protein for binding of ECT2 to the Septin/Anillin 
complex to facilitate both regulation and localisation of 
the CCF and for stability of anaphase spindle midlines 
[12, 24]. Septin/Anillin regulation of CCF contraction is 
through crosslinking actin, myosin II and RhoA [25, 26] to 
facilitate actin-dependent myosin contraction at the CCF 
[27]. In a similar fashion as tubulin, TTFields would exert 
rotational stress on Septin, and most likely many other 
proteins involved within CCF formation/regulation and 
progression through anaphase. 
Lastly, in combination with previously discussed 
protein interactions, TTFields also disrupt mitosis 
through membrane blebbing at times coinciding with 
the onset of anaphase [10, 12, 22]. The most probable 
causes of such violent blebbing observed as a response 
to TTFields would be; i) aberrant localisation of CCF 
contractile elements, producing ectopic cleavage furrows 
[12] and ii) dielectrophoretic forces acted upon the CCF 
[4, 10, 12]. TTFields in combination with the mitotic cell’s 
morphological changes (a resemblance to an hourglass) 
during the formation of the two daughter cell produces a 
non-uniform intracellular electric field, with the highest 
electric field density at the CCF directly between the 
dividing cells [22]. As described previously, sufficiently 
polar organelles and other macromolecules will gravitate 
towards the point of the greatest electric field intensity – 
the CCF, further disrupting the intricate mitotic process. It 
has been noted that these mechanisms are responsible for 
membrane disruption analogous to membrane blebbing [4, 
10, 12, 28].
Overall, these results demonstrate how TTFields 
appear to affect mitotic cells throughout the latter stages 
of/and subsequent to metaphase [12, 29]. Literature has 
also demonstrated that the anti-mitotic effects of TTFields 
operates in both a p53-dependent [12] and –independent 
[30] manner. Also, this presents TTFields as a ‘new wave’ 
mitotic inhibitor due to the metaphase/anaphase specific 
disruption paradigm, where other mitotic inhibitors 
and traditional therapies mediate anti-tumour effects 
by triggering the G1/S or G2/M checkpoints of the cell 
cycle [12, 31, 32]. This could potentiate a synergistic 
effect of TTFields with other therapies affecting mitosis 
in combination from a more ‘complete’ coverage of the 
mitotic cycle. 
TTFIELDS IN BRAIN TUMOUR 
CLINICAL TRIALS
The first-in-human pilot trial was conducted 
between 2004 and 2007 following encouraging in vitro 
and animal study data. The study assessed the safety and 
efficacy of TTFields therapy using the NovoTTF-100a 
system in 10 patients with recurrent GBM [13]. Overall; 
the patients had a median overall survival (OS) of 14.4 
months, a 1-year survival rate of 67.5% and a median time 
until tumour progression of 6.0 months [13]. Notably, 
there were 2 patients who demonstrated an 84 and 87 
month survival from TTFields therapy initiation with 
no radiological or clinical evidence of recurrent disease 
[33]. The most common side effect associated with the 
NovoTTF-100a system was contact dermatitis, which 
will be a recurrent theme with TTFields therapy, which 
results from hydrogel-induced localised irritation of the 
scalp underneath the transducer arrays of the NovoTTF-
100a [33].
Recurrent GBM (EF-11 Trial)
Following the trial conducted by Kirson et al., [13], 
the pivotal phase III trial was conducted between 2006 and 
2009 with the primary end-point being OS [34]. The trial 
was seeking to assess NovoTTF-100a as a monotherapy 
and to compare the treatment to best physician’s choice 
chemotherapy (BPC) for recurrent GBM patients 
(n = 237). The patients of the trial were randomized (1:1) 
to TTFields monotherapy (n = 120) or BPC (n = 117); 
patients of the BPC arm were administered either a 
single agent or combinational therapy regime containing; 
Bevacizumab (31%), Irinotecan (31%), BCNU/CCNU 
(25%), Carboplatin (13%), TMZ (11%), PCV (9%), other 
agents (7%) or none received (3%). Balance was achieved 
between treatment arms in regard to patient characteristics; 
90% of patients were at second or more recurrence, the 
patient’s median age was 54 years and 19% of patients had 
previously been treated with Bevacizumab [34].
NovoTTF-100a therapy demonstrated very similar 
efficacy to the chemotherapies selected by the physicians, 
with the NovoTTF-100a arm having a median OS of 6.6 
months compared to 6.0 months for the BPC arm (Hazard 
ratio (HR) = 0.86 [95% Confidence interval (CI), 0.66 – 
1.12]; p = 0.27). Again, this was true for the progression-
free survival (PFS) and the overall response rate. The PFS 
at 6 months was 21.4% for the NovoTTF-100a arm versus 
15.1% for the BPC arm (HR = 0.81 [95% CI, 0.60–1.09]; 
p = 0.13), with the overall response rate being 14.0% and 
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9.6% (p = 0.19) for the NovoTTF-100a and BPC arms 
respectively [34]. However, differences between the 
treatment modalities become apparent when considering 
their respective safety profiles. A greater frequency of 
systemic toxicities, including Grade 3/4 haematological 
(17% of patients), gastrointestinal (17%), and infections 
(8%) was apparent in the BPC arm compared to the 
NovoTTF-100a demonstrating a 4%, 3% and 4% 
frequency of occurrence (p < 0.05; Fisher exact test) 
[34]. Quality of life was also observed to be higher in the 
NovoTTF-100a arm with regards to social, cognitive and 
emotional functioning, however, self-reported physical 
functioning was slightly worse than the BPC arm [34]. The 
decline of the NovoTTF-100a treated patients’ physical 
functioning may be due to the relatively cumbersome 
nature of the NovoTTF-100a system, as well as the high 
compliance requirements for effective TTFields therapy. 
Completion of this Phase III trial and the subsequent 
post-hoc analyses [35, 36] gave some insight into 
therapeutic potential of TTFields. Firstly, NovoTTF-
100a therapy has similar efficacy as chemotherapy 
for patients with recurrent GBM but with a far more 
favourable side-effect profile [34]. Secondly, compliance 
with the NovoTTF-100a system was the main predictor 
of improved OS for patients. Kanner et al. reported a 
significantly longer median OS for NovoTTF-100a treated 
patients when compliance of 75% or greater is achieved 
(i.e. mean compliance of 18 hours or more per day) with 
a median OS of 7.7 months for the ≥75% compliance 
patients versus 4.5 months for the <75% compliance 
patients (p = 0.042). Interestingly, this post hoc analysis 
also described a significant stepwise correlation between 
median OS and compliance, with median OS of 5.8, 6.0 
and 7.7 months for <60%, 60%–79%, and 80%–99% 
compliance, respectively (p = 0.039) [35]. Lastly, this 
particular Phase III trial was the first and only trial to 
date directly comparing bevacizumab efficacy to another 
monotherapy in recurrent GBM patients. 
Newly-diagnosed GBM (EF-14 Trial)
Optune therapy was more recently tested in a Phase 
III trial for newly-diagnosed GBM patients after receiving 
their initial treatment as per the Stupp protocol [3]. The 
GBM patients (n = 700) were randomized 2:1 to either 
the TTFields with adjuvant TMZ or TMZ monotherapy 
arms, respectively. The primary end-point of the trial was 
achieved at the interim as PFS in the intent-to-treat (ITT) 
population was significantly greater for the TTFields plus 
TMZ arm versus the control. The secondary end-point 
of the trial would have been achieved if the median OS 
of the per-protocol treated population was significantly 
greater in the TTFields plus TMZ arm relative to the 
TMZ monotherapy arm [37]. Analysis of the first patients 
(n = 315) at the pre-specified interim after an 18 month 
minimum follow up demonstrated increases in median OS 
and PFS. Of note, the Independent Monitoring Committee 
for the trial recommended that the trial be terminated at 
the pre-specified interim due to perceived survival benefit 
of TTFields with TMZ. This resulted in the patients of 
the TMZ monotherapy arm being provided with access to 
Optune therapy [37]. 
The median OS for the TTFields plus TMZ arm 
was 19.6 months versus 16.6 months for the TMZ 
monotherapy arm (HR 0.75; log-rank p = 0.034) in the 
ITT population, and 20.5 months versus 15.5 months 
(HR 0.67; log-rank p = 0.0072) in the as per-protocol 
population. The median PFS in the ITT population 
was 7.1 months versus 4.0 months (HR 0.6; log-rank 
p = 0.0014) for the TTFields plus TMZ and the TMZ 
monotherapy arms, respectively [37]. As with the EF-11 
trial, the addition of TTFields therapy did not produce 
any significant increases in systemic toxicities relative 
to chemotherapy alone. This was too be expected as 
TTFields were localised to the head, but similarly, this 
was associated with a significant increase in localized skin 
toxicities; 43% of patients receiving TTFields therapy 
experienced mild to moderate skin irritation, as well as 
2% experiencing severe skin reactions (Grade 3) [37]. 
The overwhelming majority of these toxicities are skin 
rash/irritation based, and the nature and incidence rates 
of these toxicities in further studies are described here 
[38]. These TTFields associated dermatological toxicities 
may be managed prophylactically, as well as being treated 
should toxicities develop. The prophylactic approaches 
include, but are not limited to; frequent shifting of 
transducer array locations to minimize direct pressure to 
the scalp, particular care with application of transducer 
arrays on surgical scars, and maximising transducer 
array-skin contact may also reduce skin irritation. Once 
any dermatological toxicity develops, topical antibiotics 
and corticosteroids may be applied for infections or 
contact dermatitis and irritation, respectively [38]. A 
number of these dermatological complications arise from 
the repetitive application and removal of the transducer 
arrays, compounded by additional inflammation from the 
hydrogel used to cover the ceramic disc portion of the 
transducer arrays, as well as additional moisture from 
sweat [6, 38].
However, more recent reports on the trial’s mature 
data have shown improved patient survival following 
treatment, which follows trends seen at the interim 
analysis [37]. The median OS from initial randomisation 
is 20.9 months for TTFields/TMZ versus 16.0 months 
for TMZ alone treated patients (HR 0.63; log-rank 
p = < 0.01) [1]. Interestingly, this improvement to survival 
was also seen across 2, 3 and 4 year survival of patients 
in TTFields/TMZ versus TMZ alone; with the respective 
rates of 43% and 31%, 26% and 16%, and 13% and 5% 
(p = < 0.05 for all time points) [1].
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TTFIELDS IN COMBINATIONAL 
THERAPY
Alkylating agents
In accordance with the current standard of care, 
TMZ is used in combination with RT for patient benefit 
[3]. Two relevant highlights of this randomized phase 
III are apparent; firstly, the combinational therapeutic 
route produced a significant increase to both median OS 
(12.1 to 14.6 months) and 2-year survival (10% to 27%), 
secondly, a genetic determinant of benefit from TMZ was 
present in the form of methylation status of O-6-methyl-
guanine-DNA methyltransferase (MGMT) [3]. Similarly, 
phase III studies concerning elderly patients, showed that 
patients expressing a methylated MGMT status benefitted 
greatly from TMZ treatment, although not in combination 
with RT, further emphasises genetic predisposition to 
therapeutic response [39, 40]. MGMT functions to remove 
the highly mutagenic and genotoxic O6-methylgunanine 
residues caused by TMZ [41]. A negative feedback loop 
occurs upon MGMT-dependent repair of these methyl 
adducts whereby MGMT becomes irreversibly inactivated. 
It is in this absence of active MGMT that mismatch occurs 
during replication between methylgunanine and thymine 
and causes subsequent double-stranded breaks (DSBs) 
[41, 42]. Complimentary resistance mechanisms to TMZ, 
as well as other alkylating agents, are reviewed here [41]. 
Given the success of the initial trial, the EF-14 trial 
sought to evaluate the potential benefit of combining 
TTFields with TMZ compared to TMZ alone following 
chemoradiation in newly diagnosed GBM patients. As 
discussed previously, the current EF-14 trial data has 
shown promising additive efficacy of TTFields with TMZ 
[1, 37]. Silginer and colleagues investigated TTFields 
in combination with TMZ in pre-clinical glioma models 
focussing on MGMT-status and TMZ-resistance [43]. 
The study highlighted that TTFields’ efficacy was not 
dependent on MGMT expression, nor was it diminished 
within TMZ-resistant cell lines [43]. The lack of overlap 
between the TTFields and TMZ-resistance mechanisms 
is not wholly unexpected however, as the primary 
mechanism of action for TTFields has yet to be shown to 
interact with MGMT [14, 44]. This feature of the study 
highlights how TTFields may be an attractive therapeutic 
option for patients whom would not benefit greatly from 
TMZ treatment i.e. patients with a negative MGMT 
methylation status [44].
A proposed mechanism of synergism would be 
that TTFields may potentially influence DNA fragment 
orientation to perturb DSB-repair mechanisms [45]. A 
common theme will emerge that TTFields in combinational 
therapeutic routes appear to have positive synergistic 
effects without any known overlapping toxicities.
Radiation therapy
Radiation therapy (RT) represents another physical 
treatment modality for cancer treatment. The high-energy 
ionizing radiation used for treatment damages the DNA of 
targeted cancerous cells, as well as normal cells which are 
adjacent to the targeted cells [46]. RT may be delivered 
to the patient through two different means; external beam 
radiation or through internal radiation sources, with 
external radiation being delivered via high-energy protons, 
photons or particle radiation [46]. Adjuvant RT would be 
utilised to target any residual tumour remaining following 
the resection albeit following a 4 week post-surgery 
recovery period [47]. As with other therapies, RT achieves 
therapeutic efficacy predominantly through a variety of 
DNA lesions; notably single- (SSBs) and DSBs [48]. It 
is these lesions which induce cell death via apoptosis and 
mitotic catastrophe [49, 50].
Given that TTFields influence polar molecules, 
TTFields should theoretically interact with the 
fragmented DNA strands following RT. Similar to how 
TTFields disrupt microtubule assembly [4, 10, 12, 
14], TTFields may be able to influence DNA fragment 
orientation in a fashion to decrease DNA ligation to 
reduce the effectiveness of DNA repair mechanisms. 
This phenomenon has been reported on previously [45, 
51] with reports of reduced clonogenic survival and cell 
viability despite the increased number of Rad51 and 
γ-H2AX foci when TTFields and radiation treatment 
were used in combination. This report suggests a 
reduction in DNA strand break repair competency due 
to the reduction in cell survival despite the upregulation 
of DNA repair markers Rad51 [52] and γ-H2AX [53]. 
More recently, the effects of TTFields in combination 
with radiation treatment were more intently interrogated, 
with an emphasis on timing TTFields with regards 
to RT [54, 55]. Kim and colleagues reported on the 
synergistic properties of TTFields with ionising radiation 
when TTFields were given prior to radiation treatment 
[54]. The combinational therapeutic route resulted in 
greater amounts of p53-dependent apoptosis, as well 
as produced mitotic anomalies indicative of TTFields 
treatment – multi-nucleated phenotype and both mono-
polar and multi-polar spindle structures [14, 54]. Giladi 
and colleagues also investigated this combination but 
with TTFields following RT [55]. Again, it was shown 
that efficacy of RT may be increased with TTFields 
when administered following radiation treatment. Taken 
together, these reports suggest that TTFields may be used 
as a strategy to sensitise glioma to RT, whether TTFields 
is administered before or after RT. These interactions 
pose an interesting synergy paradigm which may be 





Bevacizumab is a humanised monoclonal antibody 
which antagonizes Vascular endothelial growth factor 
(VEGF) to inhibit binding to VEGF-Receptor (VEGFR) 
[56]. Bevacizumab acquired US Food and Drug 
Administration (FDA) approval for the treatment of 
recurrent GBM, following two Phase II studies – [57] 
and [58] in 2009. In summary, both studies concluded 
that Bevacizumab use was associated with a higher 
PFS. However, subsequent studies have shown that 
Bevacizumab does not significantly increase median 
OS when administered as a front-line therapy for 
newly diagnosed GBM patients [59, 60]. Furthermore, 
Bevacizumab has been associated with a number of 
negative side effects; decline in neurocognitive function, 
gastrointestinal perforation, thromboembolic events, renal 
failure, hypertension, neutropenia and overall decreased 
quality of life [56, 59–61]. It appears that the majority of 
the lower-grade adverse effects appear to be indicative of 
VEGF disruption in non-cancerous cells. 
As with other combinational therapeutic routes, 
TTFields combined with Bevacizumab is intriguing 
as both have shown promise for patients, albeit 
Bevacizumab only for recurrent GBMs [56], and may 
provide additive efficacy. Firstly, TTFields efficacy has 
been shown in a large phase III trial to be comparable to 
BPC chemotherapies, including Bevacizumab (31% of 
patients), but without a diverse and adverse effects profile 
akin to conventional chemotherapies [34]. Lastly, there has 
been evidence to suggest that TTFields may increase the 
safety profile of Bevacizumab when used in combination 
for treatment of recurrent gliomas [62]. Although on a 
small scale, Elzinga et al. retrospectively analysed patients 
(n = 20) treated with the combination of TTFields with 
Bevacizumab and found no instances of intracranial 
haemorrhage or thromboembolic events [62]. These 
particular events occur in 3% and 2.4–12.5% of patients 
treated with Bevacizumab respectively [56], although it is 
worth noting that spontaneous intracranial haemorrhage 
occurs in roughly 2% of patients without Bevacizumab 
treatment [56]. However, the exact molecular nature, if 
any, of these synergistic events has yet to be elucidated 
and should be a topic of future research. Lastly, 
bevacizumab is known to reduce vasogenic brain oedema, 
thereby reducing patients’ dexamethasone requirements. 
The significance of reducing a patient’s dexamethasone’s 
dosage will be expanded upon in later sections.  
Mitotic inhibitors
Given the intricate, yet inherently unstable mitotic 
process in proliferative cells, many inhibitors have been 
explored for the treatment of cancers; including anti-
microtubular, anti-kinase and other molecular targets. 
The induction of mitotic cell death (MCD) is the rationale 
behind targetting mitosis in cancer cells. Dividing cells 
are highly susceptible to MCD when exposed to disruptive 
stresses [63]. It is these stresses which have the potential 
to activate the spindle assembly checkpoint (SAC), 
leading to a prolonged mitotic arrest where a number of 
different cell fates are actualized, albeit intra- and inter-
line variations in cell fates are expected [64]. Combining 
TTFields with SAC inhibitors has been investigated [65], 
and demonstrated increased levels of apoptosis and G2/M-
phase accumulation of cells.
The anti-microtubular class of mitotic inhibitors 
can be divided into two distinct sub classes; microtubular-
stabilizing (i.e. Taxanes and Epothilones) and 
microtubular-destabilizing agents (i.e. Vinca alkaloids) 
[66]. These agents have demonstrated anti-tumour activity 
in a variety of tumours such as breast, non-small cell lung 
and ovarian cancer [67]. The microtubule-stabilizers, such 
as Paclitaxel, typically bind β-tubulin with high affinity 
to induce conformational changes which in turn results 
in stability of tubulin interactions [66, 68]. Conversely, 
the microtubule-destabilizers, such as Vinblastine, target 
microtubule polymerization through binding the vinca 
domain of both tubulin monomers and microtubules, 
causing the necessary conformational changes to reduce 
microtubule formation [66, 68]. Although dissimilar, 
both subclasses aim to cause MCD in a SAC-dependent 
manner. However, there has been limited transfer from 
laboratory to clinical practice for the majority of mitotic 
inhibitors [67]. This may in part be due to two main 
limitations; i) the phenomenon of mitotic slippage to 
circumvent mitotic arrest/MCD and ii) G2/M selective 
inhibition. Firstly, the polyploid phenotype typical of 
cells following mitotic arrest presents a paradigm where 
multiple cell fates are a result, with cells either succumbing 
to MCD in the subsequent G1 phase, senescence or 
existing as viable multiploidal cells [69]. The latter has 
the potential to produce cells with increasing degrees of 
instability from subsequent cell cycles, an overall increase 
in cellular stress, chemoresistance and is a predictor of 
intrinsic taxane resistance [70, 71]. The selective nature 
of mitotic inhibitors naturally leads to limitations in drug 
efficacy. Considering drug retention times as well as 
mitotic-specific drugs targetting mitotic machinery at the 
G2/M-M-phase, a large population of G1- and S-phase 
cells may remain refractory to the cytotoxic treatment 
[67]. Compounding this selectivity, the mitotic index of 
human tumours has been estimated to be less than 1% with 
mean doubling times of a range of solid tumours ranging 
from ~100 to ~400 days summarized by Komlodi-Pasztor 
et al. [72]. These observations of substantial doubling 
times and low mitotic indexes of solid tumour emphasise 
the necessity of chronic treatment over a period of 
multiple months of mitotic inhibitors. However, 
significant dose-limiting toxicity has been associated with 
tubulin-targetting agents—notably neutropenia [67, 73]—
which has been a persistent challenge during the drug 
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development process. Therefore, improving drug half-life 
and/or drug delivery limitations, while simultaneously 
reducing the dose-limiting toxicities associated with 
tubulin-targetting agents, may be a promising area of 
investigation for improving mitotic inhibitory therapy for 
patients. 
Mitotic kinase or associated protein inhibitors 
may also be a viable option for the treatment of cancer. 
More selective protein or kinase inhibitors seem to be 
attractive therapeutic options as they add more options for 
drug resistant tumours but have also been found to have 
less associated toxicities than their tubulin-associated 
counterparts on the whole [67, 72, 73]. Members of the 
Polo-like kinase (PLK) and Aurora kinase families are 
of particular interest to anti-mitotic therapies given their 
relatively restricted expression to M-phase, with minimal 
to null expression in G0, G1 and S-phases [73]. PLK1 and 
Aurora kinases are involved with multiple mitotic process 
including spindle assembly, cytokinesis, chromosome 
segregation and activation of the SAC [67, 74, 75]. Similar 
to microtubular associated therapies, inhibition of PLK1 
and Aurora Kinase A in GBM cells appears to activate the 
SAC, cause MCD and mitotic arrest [76, 77]. However, 
given that both PLK1 and Aurora Kinase A expression 
appears at S-phase and peaks at the G2/M checkpoint 
[78, 79], combining these kinase inhibitors with the 
microtubule associated agents may provide greater 
therapeutic efficacy through a more complete coverage of 
the cell cycle. 
TTFields may be considered as a physical novel 
mitotic inhibitor, so combining TTFields with biological 
mitotic inhibitors would appear logical. Firstly, assuming 
compliance to the Optune TTFields system is in the upper 
bracket of patient beneficial compliance (18 hours and 
above) [35], TTFields may overcome the limitations of 
mitotic inhibitor drug retention. Synergism between 
TTFields and mitotic inhibitors, particularly microtubule-
stabilizers, has been demonstrated and novel mechanisms 
of increased efficacy have been postulated [80, 81]. 
Kirson et al., suggested that as paclitaxel promotes 
microtubule elongation due to greater stability of tubulin 
dimers, TTFields would demonstrate greater influence 
over the microtubules due to the now greater dipole 
moment to increase microtubule misalignment [81, 82]. 
This is because the displacement vector of the positive 
to the negative charge is a function of an electric dipole 
moment. However, TTFields were shown to disrupt 
microtubules, through yet to be determined mechanisms, 
which may decrease paclitaxel efficacy in GBM [14]. 
More recently, Voloshin and colleagues investigated the 
potential for synergism of paclitaxel and TTFields in 
ovarian cancer cell lines [83]. The highlights of this study 
were the increased efficacy of TTFields when combined 
with paclitaxel, as well as increased accumulation of 
cells in the G2/M phase of the cell cycle when analysed 
with flow cytometry. However, accumulation of Caov-3 
and OVCAR-3 cells in the G2/M phase of the cell cycle 
significantly increased relative to controls following 72 
hours of TTFields treatment with A2780 cells fate being 
accumulation in the G1 phase following extended exposure 
to TTFields [83]. The differences between cell fates is 
further highlighted within the combination indexes (CI) 
of the cells; specifically, the A2780, OVCAR-3 and Caov-
3 cell lines had Cis of 1.03, 0.81 and 0.86 respectively 
[83]. These data indicate a synergistic paradigm for the 
OVCAR-3 and Caov-3 cell lines but an additive effect 
for the A2780 cell line, however these observations may 
be due to differences in the intrinsic sensitivities of the 
cell lines to mitotic inhibitor treatment. Ovarian cells 
treated with TTFields in combination with paclitaxel 
also demonstrated multipolar spindle formations, which 
coincides with previous observations of TTFields treated 
cells [14].
It is conceivable the TTFields combined with 
microtubule-destabilizing agents, such as the vinca 
alkaloids, should produce a similar effect given their 
similar modes of action. This hypothesis gains credence 
from evidence of combinational therapy consisting of 
paclitaxel and vinorelbine, a semi-synthetic vinca alkaloid, 
significantly improving outcome for breast cancer patients 
[84]. Interestingly, evidence of combining the microtubule 
associated paradigms has also appeared in nature with 
both classes being present within the roots and rhizomes 
of the bat flower, Tacca sp [85]. Lastly, it has been shown 
that TTFields do not perturb localisation of PLK1 from its 
functional location at the anaphase spindle midline [12], 
but data regarding other mitotic associated proteins has 
yet to be collected. Therefore, there is reasoning behind 
combining TTFields with a number of mitotic inhibitors 
regardless of the mitosis stage of their action.
Immunotherapy
Just as the previously detailed therapeutic options 
available to GBM patients, immunological agents may 
have the potential for synergism with TTFields, and 
thus improved efficacy. Although a newly emerging 
phenomenon, TTFields indeed seem to induce an immune 
response and its anti-tumour effects may be, at least in 
part, dependent on the competence of the patient’s immune 
system [29, 81, 86, 87]. Firstly, TTF-induced mitotic exit 
subjects the affected cells to cellular stress which among 
others, upregulates cell surface expression of calreticulin 
– an endoplasmic reticulum chaperone protein [88], a 
downregulation of anti-phagocytic signalling molecules 
such as the cell surface CD47 [89], as well as promotes 
secretion of HMGB1 in order to produce an immunogenic 
phenotype [90]. This response termed ‘Immunogenic 
cell death’ is a documented phenomenon of cancer cells 
when subjected to TTFields, which is dissimilar to the 
inherently immunosuppressive apoptosis [88, 90]. There 
is evidence in favour of TTFields promoting anti-tumour 
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immunogenicity in vitro and in vivo [81, 86, 87]. Kirson et 
al. demonstrated how TTFields may inhibit metastasis to 
the lungs of solid tumours but also noted that significantly 
greater amounts of infiltrative immune cells were found 
intratumourally in the metastasis [87]. Immune cells 
bearing the markers CD4, CD8 and CD45 were among 
the infiltrative cells, inferring a T-cell mediated response, 
but this was only true for the TTFields treated rabbits as 
opposed to the TTFields treated mice [87]. A few potential 
reasons for this discrepancy are apparent: i) species 
differences; ii) cancer cell line differences; iii) tumour 
volume differences; iv) TTFields treatment duration 
differences. Naturally, differences in cell lines used, as 
well as species would equate to differences in efficacy of 
treatments and competency of the immune system [91]. 
Lastly, significant differences in exposure durations to 
TTFields (1 week for mice and 5 weeks for rabbits) would 
account for differences in response, and indeed highlights 
a potential dose-dependent relationship between TTFields 
and an effective immune response. The significance of this 
dose-dependent relationship was highlighted in both the 
EF-11 [34] and EF-14 [1] human trials, so it should be 
expected that longer treatment duration should result in 
improved treatment outcome. 
Wong et al. 2014 had previously observed that 
patients with previous low-grade glioma histology and low 
dosing of dexamethasone in the Phase III trial examining 
response rates of NovoTTF-100A as a monotherapy 
relative to the best physicians choice (BPC) chemotherapy 
had a more favourable outcome [92]. Although, it is 
well recognised that patients with a secondary-GBM, 
have a significantly more favourable prognosis and 
longer survival [93]. Neuro-oncologists traditionally use 
dexamethasone for patients with malignant brain tumours 
for its anti-oedema effects [94]. However, dexamethasone 
does exhibit profound immunosuppressive influence 
over patients [94], and therefore has the potential to 
reduce efficacy of TTFields. Wong et al. 2015 further 
examined the effect of dexamethasone on patients and 
determined a threshold of dexamethasone exposure 
for preferential survival with TTFields treatment [86]. 
Using an unsupervised mathematical algorithm, it was 
determined that patients receiving over 4.1mg/day had a 
2.3-fold decrease in median OS for the TTFields treated 
cohort, compared to a 1.5 fold decrease in median OS for 
the BPC chemotherapy treated cohort [86]. A decrease in 
median OS was also seen with a progressive decrement 
in both cohorts until about 8.0 mg/day was achieved 
where there was no further significant effect on median 
OS [86]. However, it could also be assumed that patients 
requiring higher doses of dexamethasone may be stratified 
as higher-risk patients, so may therefore have a lower 
expected OS irrespective of TTFields.
Given that TTFields have not been shown to have 
any consequential effects on immune system competence, 
unlike traditionally used therapeutics [95], TTFields 
combined with immunotherapeutics gain credence for 
a number of reasons. Firstly, as stated above TTFields 
do not compromise the immune system as other agents 
do, potentially reducing the required dose of concurrent 
therapeutics. This dosage reduction should in turn reduce 
their inherent immune compromising nature. Secondly, 
the physical nature of TTFields appears to improve the 
infiltrative capacity of CD4 and CD8 cells in rabbit 
models [87], this should have clear synergistic effects with 
immunotherapeutics such as dendritic cells [96]. However, 
this potential synergism has yet to be studied and may be 
the key to bring the promising field of immunotherapeutics 
closer to the clinic for GBM patients [97, 98].
Novel agents
Undiscovered and potentially confounding 
synergistic properties may of course be present with a 
multitude of other novel or repurposed agents. This is 
evident through preliminary reports of TTFields with 
Bevacizumab [62], as well as TTFields combined with 
Triflouropromazine, an approved antipsychotic drug. 
Triflouropromazine has been identified to inhibit mitotic 
slippage and yet did not decrease slippage when used in 
combination with TTFields [99, 100]. This is particularly 
interesting as the treatment appeared to decrease cell 
counts by up to 14% when used in combination, suggesting 
an improvement to efficacy independent of mitotic 
slippage. Cells treated in combination also experienced 
an increase in cell size of up to 35%, a well-documented 
phenomenon of TTFields [101], as well as a reduced 
clonogenic potential of the cells [99]. These results taken 
as a whole may encourage further investigation into 
TTFields in combination with novel and repurposed drugs. 
More recently, TTFields were combined with 
Withaferin A [102], a steroidal lactone originating from 
the winter cherry plant, Withania somnifera [103]. 
Withaferin A had been previously shown to have efficacy 
against glioma cell lines in vitro as well as in murine 
orthotopic GBM models [104]. As has been a theme with 
other combinational therapeutic strategies with TTFields, 
greater efficacy is achieved when combining TTFields 
with Withaferin A compared to each treatment alone 
[102]. The mechanisms of Withaferin A have yet to be 
fully described, though reports have identified Withaferin 
A to affect expression of transcription factors, such as 
NF-κB [105]. NF-κB affects cytoskeletal assembly/
disassembly [106], so this most likely one of the reasons 
why Withaferin A is also implicated in this process [107]. 
Interestingly, genome-wide expression analytical 
approaches are emerging for TTFields treated cell lines in 
order to further describe mechanisms of action, but also to 
attempt to characterise low-responsive vs high-responsive 
cell lines [108]. Karanam and colleagues provided data 
showing differential expression of multiple canonical 
pathways between responsive and low-responsive cell 
Oncotargetwww.oncotarget.com
36640
lines [108]. Producing similar data within brain tumour 
cell lines may be able to provide further direction towards 
more targeted combinations.
CONCLUSIONS
This review has outlined and discussed the current 
literature on TTFields and its interactions with various 
therapeutic agents. However, given the limited efficacy 
of TTFields as a monotherapy [34], a need for a clear 
mechanism of action is apparent. There already exists 
ample descriptive preclinical studies at the cellular level 
for proposed mechanisms of action [12, 14], but there is a 
lack of mechanistic studies across more complex models 
with and without a combinational therapeutic approach. 
TTFields research is still in its relative infancy with 
ongoing research, endorsed by the success of the EF-14 
trial. The main benefit of concurrent TTFields therapy 
is predominantly focussed on the lack of overlapping 
toxicities, however, reports of contact dermatitis is frequent 
and expected. Not to be overlooked is that TTFields does 
not appear to perpetuate any consequences synonymous 
with failed therapy i.e. promoting invasion and metastasis, 
although this has yet to be studied in-depth. 
In conclusion, TTFields offers an exciting platform 
for a combinational therapeutic approach whether it is 
with novel or standard anti-tumour agents, with hopes that 
future treatment strategies may utilise these unique effects 
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